Welcome to our dedicated page for Wuxi Apptec news (Ticker: WUXAY), a resource for investors and traders seeking the latest updates and insights on Wuxi Apptec stock.
WuXi AppTec Co., Ltd. reports developments tied to its global CRDMO platform for pharmaceutical and life sciences customers. The company provides integrated research, development, and manufacturing services across Asia, Europe, and North America, with news commonly focused on operating results, continuing-operations revenue, backlog, guidance, and demand for enabling services.
Recurring updates also cover shareholder-return actions such as cash dividends, A-share repurchases and cancellations, and H-share award trust activity. Other company news includes sustainability disclosures, FTSE4Good Index inclusion, Science Based Targets initiative validation, and site-level developments such as the Nantong facility within its chemistry, biology, and testing service network.
WuXi AppTec reported Q3 2024 revenue of RMB10,461 million, up 14.6% YoY excluding COVID-19 commercial projects. For the first three quarters, revenue reached RMB27,702 million, growing 4.6% YoY excluding COVID-19 projects. Net profit attributable to owners was RMB6,533 million with diluted EPS of RMB2.24. The company's backlog grew 35.2% YoY to RMB43.82 billion. Operating cash flow increased 10.4% YoY with free cash flow of RMB5.56 billion. The company added over 800 new customers while maintaining 6,000+ active customers. Revenue from top 20 pharmaceutical companies grew 23.1% YoY to RMB11.22 billion excluding COVID-19 projects.
WuXi AppTec reported financial results for the first half of 2024. Revenue for Q2 2024 was RMB9,259 million, up 16.0% QoQ. Adjusted non-IFRS net profit increased by 28.5% QoQ to RMB4,372 million. For H1 2024, revenue excluding COVID-19 projects was RMB17,241 million, down 0.7% YoY, with an adjusted gross profit margin of 39.8%. The net profit attributable to shareholders was RMB4,240 million. Operating cash flow grew 48.3% YoY. The company added over 500 new customers and achieved a backlog of RMB43.10 billion, up 33.2% YoY. WuXi Chemistry recorded H1 revenue of RMB12.21 billion, growing 2.1% YoY. TIDES business revenue grew 57.2% YoY. WuXi Testing saw a 5.4% decline in lab testing revenue. WuXi ATU revenue dropped 19.4% YoY due to U.S. legislation impacts. For the full year, WuXi AppTec aims for revenue between RMB38.3-40.5 billion and free cash flow of RMB4-5 billion.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
WuXi AppTec reported a 5.8% increase in revenue year-over-year, reaching RMB8,964 million for Q1 2023. The net profit attributable to owners surged by 32.0% to RMB2,168 million, while diluted earnings per share (EPS) rose by 35.8% to RMB0.72. Adjusted non-IFRS net profit grew 14.1% to RMB2,342 million, and free cash flow turned positive at RMB1,682 million. Key business segments showed varying performance: WuXi Chemistry and WuXi Testing experienced revenue growth, while WuXi DDSU faced a significant revenue decline of 31.0%. The company continues to expand its global customer base, having added over 310 new customers.